How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.

Christoph WannerMasaomi NangakuBettina J KrausBernard ZinmanMichaela MattheusStefan HantelMartin SchumacherKristin OhnebergClaudia SchmoorSilvio E Inzucchi

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.

Keyphrases

cardiovascular disease
clinical trial
type diabetes
phase iii
randomized controlled trial
phase ii
social support
metabolic syndrome
red blood cell
depressive symptoms
open label